Strain identifier
BacDive ID: 138348
Type strain:
Species: Staphylococcus aureus
Strain history: CIP <- 2000, P. Courvalin, Inst. Pasteur, Paris, France <- K. Hiramatsu, Tokyo, Japan: strain Mu3
NCBI tax ID(s): 1280 (species)
version 8.1 (current version)
General
@ref: 39515
BacDive-ID: 138348
keywords: genome sequence, Bacteria, aerobe, mesophilic, Gram-positive
description: Staphylococcus aureus CIP 106415 is an aerobe, mesophilic, Gram-positive bacterium of the family Staphylococcaceae.
NCBI tax id
- NCBI tax id: 1280
- Matching level: species
strain history
- @ref: 39515
- history: CIP <- 2000, P. Courvalin, Inst. Pasteur, Paris, France <- K. Hiramatsu, Tokyo, Japan: strain Mu3
doi: 10.13145/bacdive138348.20230509.8.1
Name and taxonomic classification
LPSN
- @ref: 20215
- description: domain/bacteria
- keyword: phylum/bacillota
- domain: Bacteria
- phylum: Bacillota
- class: Bacilli
- order: Caryophanales
- family: Staphylococcaceae
- genus: Staphylococcus
- species: Staphylococcus aureus
- full scientific name: Staphylococcus aureus Rosenbach 1884 (Approved Lists 1980)
synonyms
- @ref: 20215
- synonym: Staphylococcus aureus subsp. anaerobius
@ref: 39515
domain: Bacteria
phylum: Firmicutes
class: Bacilli
order: Caryophanales
family: Staphylococcaceae
genus: Staphylococcus
species: Staphylococcus aureus
type strain: no
Morphology
cell morphology
@ref | gram stain | confidence | cell shape | motility |
---|---|---|---|---|
69480 | positive | 100 | ||
39515 | positive | coccus-shaped | no |
colony morphology
- @ref: 39515
Culture and growth conditions
culture medium
@ref | name | growth | composition | link |
---|---|---|---|---|
39515 | MEDIUM 72- for trypto casein soja agar | yes | Distilled water make up to (1000.000 ml);Trypto casein soy agar (40.000 g) | |
39515 | CIP Medium 72 | yes | https://catalogue-crbip.pasteur.fr/fiche_milieu.xhtml?crbip=72 |
culture temp
@ref | growth | type | temperature | range |
---|---|---|---|---|
39515 | positive | growth | 37 | mesophilic |
56732 | positive | growth | 37 | mesophilic |
39515 | positive | growth | 22-45 | |
39515 | no | growth | 10 | psychrophilic |
Physiology and metabolism
oxygen tolerance
@ref | oxygen tolerance |
---|---|
56732 | aerobe |
39515 | facultative anaerobe |
spore formation
- @ref: 69480
- spore formation: no
- confidence: 99.68
metabolite utilization
@ref | Chebi-ID | metabolite | utilization activity | kind of utilization tested |
---|---|---|---|---|
39515 | 606565 | hippurate | + | hydrolysis |
39515 | 17632 | nitrate | + | reduction |
39515 | 16301 | nitrite | - | reduction |
68375 | 16199 | urea | - | hydrolysis |
68375 | 29016 | arginine | + | hydrolysis |
68375 | 18257 | ornithine | - | degradation |
68375 | 4853 | esculin | - | hydrolysis |
68375 | 17634 | D-glucose | + | fermentation |
68375 | 15824 | D-fructose | + | fermentation |
68375 | 16024 | D-mannose | + | fermentation |
68375 | 17306 | maltose | + | fermentation |
68375 | 17716 | lactose | + | fermentation |
68375 | 27082 | trehalose | + | fermentation |
68375 | 16899 | D-mannitol | + | fermentation |
68375 | 16634 | raffinose | - | fermentation |
68375 | 16988 | D-ribose | - | fermentation |
68375 | 17057 | cellobiose | - | fermentation |
68375 | 17632 | nitrate | + | reduction |
68375 | 17992 | sucrose | + | fermentation |
68375 | 59640 | N-acetylglucosamine | + | fermentation |
68375 | 32528 | turanose | + | fermentation |
68375 | 22599 | arabinose | - | fermentation |
antibiotic resistance
- @ref: 68375
- ChEBI: 28368
- metabolite: novobiocin
- is antibiotic: yes
- is sensitive: yes
- sensitivity conc.: 1.8 µg
metabolite production
@ref | Chebi-ID | metabolite | production |
---|---|---|---|
68375 | 15688 | acetoin | no |
39515 | 35581 | indole | no |
metabolite tests
@ref | Chebi-ID | metabolite | voges-proskauer-test |
---|---|---|---|
68375 | 15688 | acetoin | - |
39515 | 15688 | acetoin | + |
enzymes
@ref | value | activity | ec |
---|---|---|---|
68375 | beta-glucuronidase | - | 3.2.1.31 |
68375 | pyrrolidonyl arylamidase | + | 3.4.19.3 |
68375 | alkaline phosphatase | + | 3.1.3.1 |
68375 | L-arginine arylamidase | - | |
68375 | beta-galactosidase | - | 3.2.1.23 |
68375 | beta-glucosidase | - | 3.2.1.21 |
68375 | ornithine decarboxylase | - | 4.1.1.17 |
68375 | arginine dihydrolase | + | 3.5.3.6 |
68375 | urease | - | 3.5.1.5 |
39515 | oxidase | - | |
39515 | beta-galactosidase | + | 3.2.1.23 |
39515 | alcohol dehydrogenase | - | 1.1.1.1 |
39515 | gelatinase | - | |
39515 | amylase | - | |
39515 | DNase | + | |
39515 | caseinase | + | 3.4.21.50 |
39515 | catalase | + | 1.11.1.6 |
39515 | coagulase | + | |
39515 | tween esterase | + | |
39515 | gamma-glutamyltransferase | - | 2.3.2.2 |
39515 | lecithinase | - | |
39515 | lipase | + | |
39515 | lysine decarboxylase | - | 4.1.1.18 |
39515 | ornithine decarboxylase | - | 4.1.1.17 |
39515 | phenylalanine ammonia-lyase | - | 4.3.1.24 |
39515 | protease | + | |
39515 | urease | - | 3.5.1.5 |
68382 | alkaline phosphatase | + | 3.1.3.1 |
68382 | esterase (C 4) | + | |
68382 | esterase lipase (C 8) | + | |
68382 | lipase (C 14) | - | |
68382 | leucine arylamidase | + | 3.4.11.1 |
68382 | valine arylamidase | - | |
68382 | cystine arylamidase | - | 3.4.11.3 |
68382 | trypsin | - | 3.4.21.4 |
68382 | alpha-chymotrypsin | - | 3.4.21.1 |
68382 | acid phosphatase | + | 3.1.3.2 |
68382 | naphthol-AS-BI-phosphohydrolase | + | |
68382 | alpha-galactosidase | - | 3.2.1.22 |
68382 | beta-galactosidase | - | 3.2.1.23 |
68382 | beta-glucuronidase | - | 3.2.1.31 |
68382 | alpha-glucosidase | + | 3.2.1.20 |
68382 | beta-glucosidase | - | 3.2.1.21 |
68382 | N-acetyl-beta-glucosaminidase | - | 3.2.1.52 |
68382 | alpha-mannosidase | - | 3.2.1.24 |
68382 | alpha-fucosidase | - | 3.2.1.51 |
API zym
@ref | Control | Alkaline phosphatase | Esterase | Esterase Lipase | Lipase | Leucine arylamidase | Valine arylamidase | Cystine arylamidase | Trypsin | alpha- Chymotrypsin | Acid phosphatase | Naphthol-AS-BI-phosphohydrolase | alpha- Galactosidase | beta- Galactosidase | beta- Glucuronidase | alpha- Glucosidase | beta- Glucosidase | N-acetyl-beta- glucosaminidase | alpha- Mannosidase | alpha- Fucosidase |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39515 | - | + | + | + | - | + | - | - | - | - | + | + | - | - | - | + | - | - | - | - |
API ID32STA
@ref | URE | ADH Arg | ODC | ESC | GLU | FRU | MNE | MAL | LAC | TRE | MAN | RAF | RIB | CEL | NIT | VP | beta GAL | ArgA | PAL | PyrA | NOVO | SAC | NAG | TUR | ARA | beta GUR |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
56732 | - | + | - | - | + | + | + | + | + | + | + | - | - | - | + | - | - | - | + | + | - | + | + | + | - | - |
API biotype100
@ref | GLU | FRU | GAL | TRE | MNE | SBE | MEL | SAC | RAF | MTE | MAL | LAC | LTE | MbGa | MaGa | CEL | GEN | MbGu | ESC | RIB | ARA | XYL | PLE | RHA | FUC | MLZ | DARL | LARL | XLT | DUL | TAG | GLY | INO | MAN | MTL | TUR | SOR | ADO | HBG | LYX | ERY | MDG | 3MDG | SAT | MUC | LTAT | DTAT | MTAT | DMLT | LMLT | CATE | TATE | TTE | CIT | GRT | GAT | 2KG | 5KG | TRY | NAG | GNT | PAC | PAT | pOBE | QAT | GTE | mOBE | BAT | PPAT | CMT | TGE | BET | PCE | ABT | HIN | LAT | CAP | CYT | HIS | SUC | FUM | GRE | GYT | AVT | ETN | TTN | GLN | ITA | 3OBU | APT | GTT | PRO | DALA | LALA | SER | MNT | PROP | TYR | 2KT |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39515 | + | + | + | + | + | - | - | + | - | + | + | + | + | - | - | - | - | + | - | + | - | - | - | - | - | - | + | - | - | - | - | + | - | + | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | + | + | - | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | + | + | - | - | - | - | - | + | - | - | + | + | + | - | - | + | - | - | - | + |
Isolation, sampling and environmental information
isolation
@ref | country | origin.country | continent | sample type |
---|---|---|---|---|
39515 | Japan | JPN | Asia | |
56732 | Japan | JPN | Asia | Human lung |
39515 | Japan | JPN | Asia | Human, Lung |
isolation source categories
Cat1 | Cat2 | Cat3 |
---|---|---|
#Host | #Human | |
#Host Body-Site | #Oral cavity and airways | #Lung |
Safety information
risk assessment
- @ref: 39515
- biosafety level: 2
- biosafety level comment: Risk group (French classification)
Sequence information
Genome sequences
- @ref: 66792
- description: Staphylococcus aureus strain NRS2
- accession: 1280.4823
- assembly level: wgs
- database: patric
- NCBI tax ID: 1280
Genome-based predictions
predictions
trait | prediction | confidence | training_data |
---|---|---|---|
spore-forming | no | 83 | no |
motile | no | 89.009 | no |
gram-positive | yes | 89.308 | no |
anaerobic | no | 99.469 | yes |
aerobic | yes | 89.852 | yes |
halophile | yes | 93.135 | no |
spore-forming | no | 92.562 | no |
glucose-util | yes | 89.161 | no |
flagellated | no | 91.392 | no |
thermophile | no | 99.763 | yes |
glucose-ferment | yes | 86.147 | yes |
External links
@ref: 39515
culture collection no.: CIP 106415, ATCC 700698, CCUG 45316, Mu 3
literature
topic | Pubmed-ID | title | authors | journal | DOI | year | mesh | topic2 |
---|---|---|---|---|---|---|---|---|
Pathogenicity | 9684652 | The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. | Hiramatsu K | Am J Med | 10.1016/s0002-9343(98)00149-1 | 1998 | Anti-Bacterial Agents/*pharmacology, Drug Resistance, Microbial, *Drug Resistance, Multiple, Humans, Japan, *Methicillin Resistance, Microbial Sensitivity Tests, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology | |
Metabolism | 9738837 | Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. | Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K | J Antimicrob Chemother | 10.1093/jac/42.2.199 | 1998 | Acetylglucosamine/metabolism, Anti-Bacterial Agents/*pharmacology, Autolysis, *Bacterial Proteins, Carrier Proteins/biosynthesis/genetics, Cell Wall/metabolism, Culture Media, Drug Resistance, Microbial, Drug Resistance, Multiple, *Hexosyltransferases, Humans, Methicillin Resistance/*physiology, Muramoylpentapeptide Carboxypeptidase/biosynthesis/genetics, N-Acetylmuramoyl-L-alanine Amidase/biosynthesis, Penicillin-Binding Proteins, Peptidoglycan/metabolism, *Peptidyl Transferases, Staphylococcus aureus/drug effects/*metabolism/ultrastructure, Vancomycin/*pharmacology | Pathogenicity |
Metabolism | 9786471 | Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. | Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K | J Antimicrob Chemother | 10.1093/jac/42.3.315 | 1998 | Amino Acids/analysis, Drug Resistance, Microbial, Glutamine/chemistry/metabolism, Microbial Sensitivity Tests, Peptides/chemistry/isolation & purification/*metabolism, Peptidoglycan/chemistry/*metabolism, Phenotype, Protein Conformation, Staphylococcus aureus/classification/drug effects/*metabolism, Vancomycin/antagonists & inhibitors/*metabolism/pharmacology | Phylogeny |
Cultivation | 9836124 | [A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin (hetero-VRSA)]. | Hanaki H, Inaba Y, Sasaki K, Hiramatsu K | Jpn J Antibiot | 1998 | Anti-Bacterial Agents/*pharmacology, Bacteriological Techniques, Culture Media, Drug Antagonism, Drug Resistance, Microbial, Lactams, Methicillin Resistance, Staphylococcus aureus/*drug effects/*isolation & purification, Vancomycin/*pharmacology | Enzymology | |
Phylogeny | 10708580 | Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. | Kuroda M, Kuwahara-Arai K, Hiramatsu K | Biochem Biophys Res Commun | 10.1006/bbrc.2000.2277 | 2000 | Anti-Bacterial Agents/*pharmacology, Base Sequence, DNA Primers, DNA, Complementary, *Down-Regulation, Drug Resistance, Microbial/genetics, Genes, Bacterial, Nucleic Acid Hybridization, Staphylococcus aureus/drug effects/*genetics, *Up-Regulation, Vancomycin/*pharmacology | Pathogenicity |
Metabolism | 11120978 | A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. | Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS | Antimicrob Agents Chemother | 10.1128/AAC.45.1.280-287.2001 | 2001 | Anti-Bacterial Agents/*metabolism/*pharmacology, Chromatography, High Pressure Liquid, Drug Resistance, Microbial, Microbial Sensitivity Tests, Peptidoglycan/chemistry/*metabolism, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/*metabolism, Teicoplanin/metabolism/pharmacology, Vancomycin/metabolism/pharmacology, Vancomycin Resistance | Pathogenicity |
Pathogenicity | 11257050 | Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. | Aritaka N, Hanaki H, Cui L, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.45.4.1292-1294.2001 | 2001 | Anti-Bacterial Agents/*pharmacology, Dose-Response Relationship, Drug, Drug Antagonism, Drug Interactions, Drug Therapy, Combination/*pharmacology, Microbial Sensitivity Tests, Peptidoglycan/biosynthesis, Staphylococcus aureus/*drug effects/metabolism, Vancomycin/*pharmacology, *Vancomycin Resistance, beta-Lactams/*pharmacology | Metabolism |
Pathogenicity | 11266410 | A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. | Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP | J Antimicrob Chemother | 10.1093/jac/47.4.399 | 2001 | *Hospitals, Humans, Methicillin Resistance, Microbial Sensitivity Tests/*methods, Phenotype, Reproducibility of Results, Sensitivity and Specificity, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/physiology, United Kingdom, Vancomycin/*pharmacology, *Vancomycin Resistance | Phenotype |
Pathogenicity | 11304997 | [Clinical relevance of hetero-VRSA in surgical infections]. | Okii K, Takesue Y, Yokoyama T | Nihon Rinsho | 2001 | Humans, Methicillin Resistance, Staphylococcal Infections/drug therapy, Staphylococcus aureus/*drug effects, *Vancomycin Resistance | ||
Pathogenicity | 11427551 | Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. | Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D | J Clin Microbiol | 10.1128/JCM.39.7.2439-2444.2001 | 2001 | Anti-Bacterial Agents/*pharmacology, Double-Blind Method, Humans, Methicillin Resistance, Microbial Sensitivity Tests/*methods/standards, Sensitivity and Specificity, Staphylococcus/*drug effects/isolation & purification, Staphylococcus aureus/drug effects, Vancomycin/*pharmacology, Vancomycin Resistance | Enzymology |
Pathogenicity | 11494564 | [Investigation of infective endocarditis clinical isolates of methicillin resistant Staphylococcus aureus non-responsive to vancomycin]. | Takayama Y, Yoshida K, Yamaguchi Y, Nonoyama M, Endo T, Sunakawa K | Kansenshogaku Zasshi | 10.11150/kansenshogakuzasshi1970.75.473 | 2001 | Endocarditis, Bacterial/drug therapy/*microbiology, Humans, Male, *Methicillin Resistance, Middle Aged, Staphylococcal Infections/drug therapy/*microbiology, Staphylococcus aureus/drug effects/*isolation & purification, Vancomycin/*therapeutic use | Enzymology |
Pathogenicity | 11724859 | Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. | Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H, Tanimoto K, Fujimoto S | J Clin Microbiol | 10.1128/JCM.39.12.4445-4451.2001 | 2001 | Anti-Bacterial Agents/pharmacology, DNA, Bacterial/analysis, Electrophoresis, Gel, Pulsed-Field, *Hospitals, Humans, Japan/epidemiology, *Methicillin Resistance, Microbial Sensitivity Tests, *Population Surveillance, Staphylococcal Infections/epidemiology/microbiology/*transmission, Staphylococcus aureus/*drug effects, Vancomycin/pharmacology, *Vancomycin Resistance | Enzymology |
Pathogenicity | 12718825 | Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient--importance of low-level resistance to vancomycin. | Haraga I, Nomura S, Fukamachi S, Ohjimi H, Hanaki H, Hiramatsu K, Nagayama A | Int J Infect Dis | 10.1016/s1201-9712(02)90165-7 | 2002 | Anti-Bacterial Agents/pharmacology/*therapeutic use, Child, Preschool, Culture Media, Genotype, Humans, Male, *Methicillin Resistance, Microbial Sensitivity Tests, Phenotype, Staphylococcal Infections/*drug therapy/microbiology, Staphylococcus aureus/classification/*drug effects/genetics/isolation & purification, Treatment Outcome, Vancomycin/pharmacology/*therapeutic use, *Vancomycin Resistance, Wound Infection/*drug therapy/microbiology | Cultivation |
Pathogenicity | 12808315 | Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA). | Kim YS, Kiem S, Yun HJ, Jung SI, Oh WS, Kim SW, Peck KR, Lee NY, Song JH | J Korean Med Sci | 10.3346/jkms.2003.18.3.319 | 2003 | Anti-Bacterial Agents/*pharmacology, Cefotaxime/pharmacology, Drug Synergism, Humans, In Vitro Techniques, Microbial Sensitivity Tests, Oxacillin/*pharmacology, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology, Vancomycin Resistance, beta-Lactam Resistance | |
Pathogenicity | 14574841 | [Epidemiological investigation of MRSA with antagonistic effects of beta-lactam antibiotic and vancomycin]. | Yamaguchi Y, Hanaki H, Barada K, Inamatu T, Sunakawa K | Kansenshogaku Zasshi | 10.11150/kansenshogakuzasshi1970.77.661 | 2003 | Anti-Bacterial Agents/*pharmacology, Drug Antagonism, Humans, Japan, *Methicillin Resistance, Retrospective Studies, Staphylococcus aureus/*drug effects/isolation & purification, Vancomycin/*pharmacology, beta-Lactams/pharmacology | Enzymology |
Metabolism | 15141945 | Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315. | Ohta T, Hirakawa H, Morikawa K, Maruyama A, Inose Y, Yamashita A, Oshima K, Kuroda M, Hattori M, Hiramatsu K, Kuhara S, Hayashi H | DNA Res | 10.1093/dnares/11.1.51 | 2004 | Bacterial Proteins/*genetics/metabolism, Cell Wall/genetics/metabolism, Drug Resistance, Microbial/genetics, Methicillin Resistance/*genetics, *Mutation, Open Reading Frames/genetics, Staphylococcus aureus/enzymology/*genetics, Vancomycin Resistance/*genetics | Enzymology |
Pathogenicity | 15164965 | In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci. | Bergeret M, Boutros N, Raymond J | Int J Antimicrob Agents | 10.1016/j.ijantimicag.2003.08.009 | 2004 | Anti-Bacterial Agents/*administration & dosage, Cephalosporins/*administration & dosage, Cross Infection/drug therapy/microbiology, Drug Resistance, Multiple, Bacterial, Drug Therapy, Combination/*administration & dosage, *Glycopeptides, Humans, In Vitro Techniques, Oxacillin/pharmacology, Staphylococcal Infections/drug therapy/microbiology, Staphylococcus aureus/*drug effects/isolation & purification, Staphylococcus epidermidis/*drug effects/isolation & purification, Staphylococcus haemolyticus/*drug effects/isolation & purification | Enzymology |
Pathogenicity | 15715719 | Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. | Nonhoff C, Denis O, Struelens MJ | Clin Microbiol Infect | 10.1111/j.1469-0691.2004.01060.x | 2005 | Belgium/epidemiology, Culture Media/chemistry, *Drug Resistance, Multiple, Bacterial, Hospitals, Humans, *Methicillin Resistance, Microbial Sensitivity Tests/methods, Prevalence, Sensitivity and Specificity, Staphylococcal Infections/epidemiology/*microbiology, Staphylococcus aureus/*drug effects/genetics, Teicoplanin/*pharmacology, Vancomycin/*pharmacology | Cultivation |
Transcriptome | 15855508 | A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. | McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA | Antimicrob Agents Chemother | 10.1128/AAC.49.5.1865-1871.2005 | 2005 | Anti-Bacterial Agents/*pharmacology, DNA Probes, DNA, Bacterial/genetics, Drug Resistance, Bacterial, Gene Expression Regulation, Bacterial/genetics, Genes, Bacterial/genetics, Microbial Sensitivity Tests, Minocycline/*analogs & derivatives/*pharmacology, Mutation/genetics, Oligonucleotide Array Sequence Analysis, Plasmids/genetics, RNA, Bacterial/genetics, Reverse Transcriptase Polymerase Chain Reaction, Staphylococcus aureus/*drug effects, Tigecycline | Pathogenicity |
Pathogenicity | 16130290 | [The combined effect of methicillin and teicoplanin against Staphylococcus aureus strains investigated in vitro]. | Mlynarczyk A, Mlynarczyk G, Luczak M | Med Dosw Mikrobiol | 2005 | Anti-Bacterial Agents/pharmacology, Drug Synergism, Drug Therapy, Combination, In Vitro Techniques, Methicillin/*pharmacology, Methicillin Resistance, Microbial Sensitivity Tests, Staphylococcus aureus/*drug effects, Teicoplanin/*pharmacology | ||
Pathogenicity | 16569879 | Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50. | Utaida S, Pfeltz RF, Jayaswal RK, Wilkinson BJ | Antimicrob Agents Chemother | 10.1128/AAC.50.4.1541-1545.2006 | 2006 | Anti-Bacterial Agents/*pharmacology, Bacteriolysis/*drug effects, Glycopeptides/metabolism/*pharmacology, Microbial Sensitivity Tests, Staphylococcus aureus/*drug effects/metabolism, Vancomycin/pharmacology | Metabolism |
Pathogenicity | 17954695 | Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. | Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.00534-07 | 2007 | Anti-Bacterial Agents/pharmacology, Bacterial Proteins/*genetics/metabolism, *Gene Expression Regulation, Bacterial, Genome, Bacterial/genetics, Humans, Microbial Sensitivity Tests, *Mutation, Oligonucleotide Array Sequence Analysis, Phenotype, Sequence Analysis, DNA, *Signal Transduction, Staphylococcus aureus/*drug effects/genetics/growth & development/metabolism, Vancomycin/pharmacology, Vancomycin Resistance/*genetics | Transcriptome |
Pathogenicity | 17962217 | Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. | Amiali NM, Mulvey MR, Berger-Bachi B, Sedman J, Simor AE, Ismail AA | J Antimicrob Chemother | 10.1093/jac/dkm400 | 2007 | Algorithms, Anti-Bacterial Agents/pharmacology, Drug Resistance, Bacterial/*drug effects, Glycopeptides/*pharmacology, Humans, Methicillin Resistance/drug effects, Microbial Sensitivity Tests, Principal Component Analysis, Reproducibility of Results, Spectroscopy, Fourier Transform Infrared/methods, Staphylococcal Infections/microbiology, Staphylococcus aureus/classification/drug effects/*isolation & purification | Phylogeny |
Pathogenicity | 18297444 | The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin. | Oshiro T, Nagasawa Z, Hanaki H, Ikeda-Dantsuji Y, Nagayama A | J Infect Chemother | 10.1007/s10156-007-0569-9 | 2008 | Anti-Bacterial Agents/*pharmacology, Bacteriolysis, *Drug Resistance, Multiple, Bacterial, Humans, Methicillin Resistance, Microbial Sensitivity Tests, Microscopy, Electron, Transmission, Minocycline/*pharmacology, Staphylococcal Infections/microbiology, Staphylococcus aureus/classification/cytology/*drug effects, Vancomycin/*pharmacology, Vancomycin Resistance | Phylogeny |
Pathogenicity | 18445959 | Modified PAP method to detect heteroresistance to vancomycin among methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital. | Iyer RN, Hittinahalli V | Indian J Med Microbiol | 10.4103/0255-0857.40537 | 2008 | Anti-Bacterial Agents/*pharmacology, Hospitals, Humans, *Methicillin Resistance, Microbial Sensitivity Tests/*methods, Predictive Value of Tests, Sensitivity and Specificity, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/isolation & purification, *Vancomycin Resistance | Enzymology |
Enzymology | 18984644 | Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. | Leonard SN, Rybak MJ | J Antimicrob Chemother | 10.1093/jac/dkn439 | 2008 | Anti-Bacterial Agents/*pharmacokinetics/*pharmacology, Colony Count, Microbial, Daptomycin/*pharmacokinetics/*pharmacology, Humans, Methicillin-Resistant Staphylococcus aureus/*drug effects, Microbial Viability, Models, Theoretical, Vancomycin/*pharmacokinetics/*pharmacology, *Vancomycin Resistance | Pathogenicity |
Pathogenicity | 19155225 | Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. | Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM | J Antimicrob Chemother | 10.1093/jac/dkp001 | 2009 | Aminoglycosides/administration & dosage/*therapeutic use, Animals, Anti-Bacterial Agents/pharmacology/*therapeutic use, Bacteremia/*drug therapy/microbiology, Blood/microbiology, Colony Count, Microbial, *Drug Resistance, Bacterial, Female, Glycopeptides/pharmacology, Lipoglycopeptides, Mice, Spleen/microbiology, Staphylococcal Infections/*drug therapy/microbiology, Staphylococcus aureus/*drug effects, Treatment Outcome, Vancomycin/administration & dosage/therapeutic use | |
Genetics | 19451283 | Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. | Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.00834-08 | 2009 | Anti-Bacterial Agents/*pharmacology, Blotting, Northern, Drug Resistance, Multiple, Bacterial, Genome, Bacterial/genetics, Imipenem/*pharmacology, Microbial Sensitivity Tests, Mutation, Sequence Analysis, DNA, Staphylococcus aureus/*drug effects/genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics, beta-Lactams/pharmacology | Transcriptome |
Pathogenicity | 19506056 | Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. | Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, Mayall BC, Johnson PD, Grayson ML | Antimicrob Agents Chemother | 10.1128/AAC.01365-08 | 2009 | Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Methicillin-Resistant Staphylococcus aureus/drug effects/*physiology, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections/*drug therapy/*microbiology/physiopathology, Staphylococcus aureus/drug effects/*physiology, Treatment Outcome, Vancomycin/*therapeutic use, Young Adult | |
Pathogenicity | 20139142 | Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. | Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM | J Antimicrob Chemother | 10.1093/jac/dkq028 | 2010 | Aminoglycosides/administration & dosage/*pharmacology/*therapeutic use, Animals, Anti-Bacterial Agents/administration & dosage/*pharmacology/*therapeutic use, Bacteremia/drug therapy, Blood/microbiology, Disease Models, Animal, Female, Lipoglycopeptides, Mice, Microbial Sensitivity Tests, Spleen/microbiology, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/*drug effects, Treatment Outcome, *Vancomycin Resistance | |
Pathogenicity | 20392906 | First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia. | Al-Obeid S, Haddad Q, Cherkaoui A, Schrenzel J, Francois P | J Clin Microbiol | 10.1128/JCM.00954-09 | 2010 | Aged, Anti-Bacterial Agents/analysis/*pharmacology/therapeutic use, Bacterial Typing Techniques, Blood/microbiology, Chromosomes, Bacterial, Cluster Analysis, DNA Fingerprinting, DNA, Bacterial/genetics, Genes, Bacterial, Genotype, Humans, Lysostaphin/pharmacology, Male, Methicillin-Resistant Staphylococcus aureus/*drug effects/*isolation & purification, Microarray Analysis, Microbial Sensitivity Tests, Microbial Viability/drug effects, Plasmids, Saudi Arabia, Sepsis/*microbiology, Serum/chemistry, Staphylococcal Infections/*microbiology, Teicoplanin/pharmacology, Vancomycin/analysis/*pharmacology/therapeutic use, *Vancomycin Resistance | Genetics |
Pathogenicity | 21048008 | Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. | Satola SW, Farley MM, Anderson KF, Patel JB | J Clin Microbiol | 10.1128/JCM.01128-10 | 2010 | Anti-Bacterial Agents/*pharmacology, Culture Media/chemistry, Humans, Microbial Sensitivity Tests/methods, Sensitivity and Specificity, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology, *Vancomycin Resistance | Cultivation |
21374408 | Detection Methods of Glycopeptide-Resistant Staphylococcus aureus I : Susceptibility Testing. | Hanaki H, Hiramatsu K | Methods Mol Med | 10.1385/1-59259-077-2:85 | 2001 | |||
21374409 | Detection Methods for Glycopeptide-Resistant Staphylococcus aureus II : Cell Wall Analysis. | Hanaki H, Hiramatsu K | Methods Mol Med | 10.1385/1-59259-077-2:93 | 2001 | |||
Pathogenicity | 21490190 | Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods. | Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R | J Clin Microbiol | 10.1128/JCM.01435-10 | 2011 | Agar, Culture Media/chemistry, Humans, Mass Screening/methods, Microbial Sensitivity Tests/methods, Sensitivity and Specificity, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/isolation & purification, *Vancomycin Resistance | Cultivation |
Pathogenicity | 21525024 | Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. | Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S | J Antimicrob Chemother | 10.1093/jac/dkr169 | 2011 | Adult, Aged, Anti-Bacterial Agents/*pharmacology/therapeutic use, Bacteremia/*drug therapy/*microbiology, Female, Humans, Male, Methicillin-Resistant Staphylococcus aureus/*drug effects/isolation & purification, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections/*drug therapy/microbiology, Treatment Outcome, Vancomycin/*pharmacology/therapeutic use, *Vancomycin Resistance | Enzymology |
Phylogeny | 21625460 | Sequence diversities of serine-aspartate repeat genes among Staphylococcus aureus isolates from different hosts presumably by horizontal gene transfer. | Xue H, Lu H, Zhao X | PLoS One | 10.1371/journal.pone.0020332 | 2011 | Animals, Aspartic Acid/*genetics, Base Sequence, Cattle, DNA, Bacterial, Female, *Gene Transfer, Horizontal, *Genes, Bacterial, Humans, Mastitis, Bovine/microbiology, Molecular Sequence Data, Phylogeny, Sequence Homology, Nucleic Acid, Serine/*genetics, Staphylococcus aureus/classification/*genetics/isolation & purification | Pathogenicity |
Pathogenicity | 21746940 | Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. | Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.00398-11 | 2011 | Anti-Bacterial Agents/*pharmacology, Bacterial Proteins/*genetics, DNA-Directed RNA Polymerases/*genetics, Microbial Sensitivity Tests, Mutation, Rifampin/pharmacology, Staphylococcus aureus/*drug effects/*genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics | |
Phenotype | 23113753 | Presence of both heterogeneous vancomycin-intermediate resistance and beta-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection. | Takata T, Miyazaki M, Futo M, Hara S, Shiotsuka S, Kamimura H, Yoshimura H, Matsunaga A, Nishida T, Ishikura H, Ishikawa T, Tamura K, Tsuji BT | Scand J Infect Dis | 10.3109/00365548.2012.723221 | 2012 | Adolescent, Adult, Aged, Aged, 80 and over, Analysis of Variance, Anti-Bacterial Agents/*pharmacology, Bacteremia/drug therapy/*microbiology, Comorbidity, Female, Humans, Logistic Models, Male, Methicillin-Resistant Staphylococcus aureus/*drug effects/isolation & purification, Microbial Sensitivity Tests, Middle Aged, Phenotype, Retrospective Studies, Staphylococcal Infections/drug therapy/*microbiology, Treatment Outcome, Vancomycin Resistance, beta-Lactams/*pharmacology | Pathogenicity |
Phylogeny | 23442205 | Global analysis of transcriptional regulators in Staphylococcus aureus. | Ibarra JA, Perez-Rueda E, Carroll RK, Shaw LN | BMC Genomics | 10.1186/1471-2164-14-126 | 2013 | Bacterial Proteins/classification/*genetics, Gene Regulatory Networks, *Genes, Bacterial, Methicillin-Resistant Staphylococcus aureus/genetics, Phylogeny, Sigma Factor/genetics, Staphylococcus aureus/*genetics, Transcription Factors/classification/*genetics | |
Pathogenicity | 24018261 | Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. | Matsuo M, Cui L, Kim J, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.00425-13 | 2013 | Anti-Bacterial Agents/*pharmacology, Cell Wall/ultrastructure, DNA-Directed RNA Polymerases/genetics, *Gene Expression Regulation, Bacterial, Genes, Bacterial, *Genome, Bacterial, High-Throughput Nucleotide Sequencing, Humans, Microbial Sensitivity Tests, *Mutation, Nucleoside-Phosphate Kinase/genetics, Staphylococcal Infections/microbiology, Staphylococcus aureus/drug effects/*genetics/growth & development/isolation & purification, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics | Genetics |
Phenotype | 24841271 | "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. | Saito M, Katayama Y, Hishinuma T, Iwamoto A, Aiba Y, Kuwahara-Arai K, Cui L, Matsuo M, Aritaka N, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.02470-13 | 2014 | Anti-Bacterial Agents/pharmacology, Bacterial Proteins/genetics, Cell Wall/drug effects/genetics/microbiology, DNA-Directed RNA Polymerases/genetics, Genome, Bacterial/genetics, Microbial Sensitivity Tests/methods, Mutation/genetics, Phenotype, Staphylococcus aureus/*drug effects/*genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics | Pathogenicity |
Pathogenicity | 24957836 | Exposure of Staphylococcus aureus to subinhibitory concentrations of beta-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus. | Roch M, Clair P, Renzoni A, Reverdy ME, Dauwalder O, Bes M, Martra A, Freydiere AM, Laurent F, Reix P, Dumitrescu O, Vandenesch F | Antimicrob Agents Chemother | 10.1128/AAC.02574-14 | 2014 | Anti-Bacterial Agents/administration & dosage/*pharmacology, Ceftazidime/administration & dosage/pharmacology, Ceftriaxone/administration & dosage/pharmacology, Drug Resistance, Bacterial, Imipenem/administration & dosage/pharmacology, Methicillin Resistance/drug effects, Microbial Sensitivity Tests, Microscopy, Electron, Transmission, Staphylococcus aureus/*drug effects/ultrastructure, Vancomycin/administration & dosage/pharmacology, Vancomycin Resistance/*drug effects, beta-Lactams/administration & dosage/*pharmacology | |
Pathogenicity | 26203181 | Adaptation to vancomycin pressure of multiresistant Staphylococcus capitis NRCS-A involved in neonatal sepsis. | Butin M, Martins-Simoes P, Picaud JC, Kearns A, Claris O, Vandenesch F, Laurent F, Rasigade JP | J Antimicrob Chemother | 10.1093/jac/dkv217 | 2015 | *Adaptation, Biological, Anti-Bacterial Agents/*pharmacology/therapeutic use, Cell Wall/ultrastructure, Humans, Infant, Newborn, Microbial Sensitivity Tests, Microscopy, Electron, Transmission, Sepsis/drug therapy/*microbiology, Serial Passage, Staphylococcal Infections/drug therapy/*microbiology, Staphylococcus/*drug effects/growth & development/ultrastructure, Vancomycin/*pharmacology/therapeutic use | |
Pathogenicity | 26311860 | Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation. | Khatib R, Riederer K, Sharma M, Shemes S, Iyer SP, Szpunar S | J Clin Microbiol | 10.1128/JCM.01620-15 | 2015 | Agar/pharmacology, Anti-Bacterial Agents/*pharmacology, Culture Media/*pharmacology, Humans, Methicillin-Resistant Staphylococcus aureus/drug effects/*growth & development/isolation & purification, Microbial Sensitivity Tests, Staphylococcal Infections/microbiology, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics | Cultivation |
Metabolism | 27067329 | Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus. | Katayama Y, Sekine M, Hishinuma T, Aiba Y, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.00420-16 | 2016 | Anti-Bacterial Agents/*pharmacology, Bacterial Proteins/genetics/metabolism, Bacteriolysis/genetics, Cell Wall/*drug effects/genetics/metabolism/ultrastructure, DNA-Directed RNA Polymerases/genetics/metabolism, Formate Dehydrogenases/genetics/metabolism, *Gene Expression Regulation, Bacterial, Genotype, Membrane Proteins/genetics/metabolism, Microbial Sensitivity Tests, *Mutation, Phenotype, Reverse Genetics/methods, Staphylococcus aureus/*drug effects/genetics/metabolism/ultrastructure, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics | Phenotype |
Transcriptome | 27476981 | Complete sequence of a plasmid from a bovine methicillin-resistant Staphylococcus aureus harbouring a novel ica-like gene cluster in addition to antimicrobial and heavy metal resistance genes. | Fessler AT, Zhao Q, Schoenfelder S, Kadlec K, Brenner Michael G, Wang Y, Ziebuhr W, Shen J, Schwarz S | Vet Microbiol | 10.1016/j.vetmic.2016.07.010 | 2016 | Animals, Anti-Infective Agents/pharmacology, Bacterial Proteins/genetics, Biofilms/*growth & development, Cattle, Cattle Diseases/epidemiology/*microbiology, Drug Resistance, Multiple, Bacterial/*genetics, Metals, Heavy/toxicity, Methicillin-Resistant Staphylococcus aureus/drug effects/*genetics/isolation & purification/pathogenicity, Microbial Sensitivity Tests/veterinary, Multigene Family, Plasmids/*genetics, Sequence Analysis, DNA/veterinary, Staphylococcal Infections/epidemiology/microbiology/*veterinary, Virulence/genetics | Enzymology |
Pathogenicity | 28139739 | Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. | Lai CC, Chen CC, Chuang YC, Tang HJ | Sci Rep | 10.1038/srep41758 | 2017 | Anti-Bacterial Agents/*pharmacology, Cephalosporins/*pharmacology, Drug Synergism, Glycopeptides/*pharmacology, Humans, Microbial Sensitivity Tests, Staphylococcus aureus/*drug effects, Teicoplanin/*pharmacology, Vancomycin/*pharmacology | |
Pathogenicity | 28289032 | VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA. | Dai Y, Chang W, Zhao C, Peng J, Xu L, Lu H, Zhou S, Ma X | Antimicrob Agents Chemother | 10.1128/AAC.02740-16 | 2017 | Anti-Bacterial Agents/*pharmacology, Bacterial Proteins/biosynthesis/*genetics/*metabolism, Bacterial Toxins/biosynthesis, DNA-Binding Proteins/*metabolism, Hemolysin Proteins/biosynthesis, Microbial Sensitivity Tests, Porins/biosynthesis, Promoter Regions, Genetic/*genetics, Quorum Sensing/drug effects, RNA, Bacterial/biosynthesis, Sphingomyelin Phosphodiesterase/biosynthesis, Staphylococcal Infections/drug therapy/microbiology/pathology, Staphylococcus aureus/drug effects/*genetics/pathogenicity, Trans-Activators/*genetics, Transcription Factors/biosynthesis, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics, Virulence/drug effects, Virulence Factors/biosynthesis | Metabolism |
Pathogenicity | 28827421 | Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. | Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF | Antimicrob Agents Chemother | 10.1128/AAC.00452-17 | 2017 | Anti-Bacterial Agents/*pharmacology, DNA-Directed RNA Polymerases/genetics, High-Throughput Nucleotide Sequencing, Humans, Methicillin-Resistant Staphylococcus aureus/*drug effects/*genetics/growth & development, Microbial Sensitivity Tests, Mupirocin/*pharmacology, Mutation/genetics, Polymorphism, Single Nucleotide/genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics | |
Pathogenicity | 29158272 | Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus. | Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen B | Antimicrob Agents Chemother | 10.1128/AAC.02100-17 | 2018 | Anti-Bacterial Agents/*pharmacology, Drug Therapy, Combination, Humans, Microbial Sensitivity Tests/methods, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology, Vancomycin Resistance/*drug effects, beta-Lactams/pharmacology | |
Pathogenicity | 30455230 | Identification of a Novel Gene Associated with High-Level beta-Lactam Resistance in Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain Mu3 and Methicillin-Resistant S. aureus Strain N315. | Matsuo M, Yamamoto N, Hishinuma T, Hiramatsu K | Antimicrob Agents Chemother | 10.1128/AAC.00712-18 | 2019 | Anti-Bacterial Agents/*pharmacology, Codon, Nonsense/genetics, Methicillin/pharmacology, Methicillin-Resistant Staphylococcus aureus/*drug effects/*genetics, Microbial Sensitivity Tests, Staphylococcus aureus/drug effects/genetics, Vancomycin/*pharmacology, beta-Lactam Resistance/genetics/*physiology | |
Pathogenicity | 31009806 | VraSR has an important role in immune evasion of Staphylococcus aureus with low level vancomycin resistance. | Gao C, Dai Y, Chang W, Fang C, Wang Z, Ma X | Microbes Infect | 10.1016/j.micinf.2019.04.003 | 2019 | Bacterial Adhesion/genetics, Bacterial Proteins/genetics/*immunology, Biofilms/growth & development, Cell Wall/genetics/metabolism, DNA-Binding Proteins/genetics/*immunology, HeLa Cells, Humans, Immune Evasion, Microbial Viability/genetics, Mutation, Neutrophils/microbiology, Staphylococcal Infections/*microbiology, Staphylococcus aureus/*genetics/*immunology, *Vancomycin Resistance/genetics/immunology | Metabolism |
31214151 | Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Uses the VraSR Regulatory System to Modulate Autophagy for Increased Intracellular Survival in Macrophage-Like Cell Line RAW264.7. | Dai Y, Gao C, Chen L, Chang W, Yu W, Ma X, Li J | Front Microbiol | 10.3389/fmicb.2019.01222 | 2019 | |||
Pathogenicity | 32001173 | Protective activity of anti-lipoteichoic acid monoclonal antibody in single or combination therapies in methicillin-resistant Staphylococcus aureus-induced murine sepsis models. | Ohsawa H, Baba T, Enami J, Hiramatsu K | J Infect Chemother | 10.1016/j.jiac.2019.12.018 | 2020 | Animals, Anti-Bacterial Agents/pharmacology/therapeutic use, Antibodies, Bacterial, Antibodies, Monoclonal/*pharmacology/therapeutic use, Daptomycin/pharmacology/therapeutic use, Disease Models, Animal, Drug Therapy, Combination, Humans, Linezolid/pharmacology/therapeutic use, Lipopolysaccharides/*antagonists & inhibitors/metabolism, Methicillin-Resistant Staphylococcus aureus/*drug effects, Mice, Sepsis/*drug therapy, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/drug effects, Teichoic Acids/*antagonists & inhibitors/metabolism, Vancomycin/pharmacology/therapeutic use | Metabolism |
Enzymology | 32233172 | Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea. | Kim HK, Choi SM, Kang G, Park KH, Lee DG, Park WB, Rhee SJ, Lee S, Jung SI, Jang HC | Yonsei Med J | 10.3349/ymj.2020.61.4.301 | 2020 | Animals, Anti-Bacterial Agents/pharmacokinetics/pharmacology/therapeutic use, Disease Models, Animal, Drugs, Generic/*pharmacokinetics/pharmacology/*therapeutic use, Methicillin-Resistant Staphylococcus aureus/*drug effects, Mice, Microbial Sensitivity Tests, Republic of Korea, Staphylococcal Infections/complications/*drug therapy/microbiology, Staphylococcus aureus/drug effects, Thigh/microbiology, Treatment Failure, Vancomycin/*pharmacokinetics/pharmacology/*therapeutic use | Pathogenicity |
Pathogenicity | 33097426 | Differentiation of qacA and qacB using high-resolution melt curve analysis, and both qacA and qacB but not qacC or norA types increase chlorhexidine minimal inhibitory concentrations in Staphylococcus aureus isolates. | Lin KH, Lin CY, Huang CC, Ho YL, Yang SF, Ho CM | J Microbiol Immunol Infect | 10.1016/j.jmii.2020.09.006 | 2020 | Anti-Infective Agents, Local/*pharmacology, Bacterial Proteins/*genetics, Chlorhexidine/*pharmacology, Disinfectants/*pharmacology, Drug Resistance, Bacterial/genetics, Humans, Membrane Transport Proteins/*genetics, Methicillin-Resistant Staphylococcus aureus/*drug effects/genetics/isolation & purification, Microbial Sensitivity Tests, Multidrug Resistance-Associated Proteins/genetics, Staphylococcal Infections/drug therapy/microbiology/prevention & control | Enzymology |
Phenotype | 33519759 | Variable Release of Lipoteichoic Acid From Staphylococcus aureus Bloodstream Isolates Relates to Distinct Clinical Phenotypes, Strain Background, and Antibiotic Exposure. | Algorri M, Jorth P, Wong-Beringer A | Front Microbiol | 10.3389/fmicb.2020.609280 | 2021 | ||
Pathogenicity | 34784023 | Efficacy and mechanism of carvacrol with octanoic acid against mastitis causing multi-drug-resistant pathogens. | Rani S, Singh H, Ram C | Braz J Microbiol | 10.1007/s42770-021-00639-4 | 2021 | Animals, Anti-Bacterial Agents/pharmacology, Caprylates/pharmacology, Cattle, Cymenes, Escherichia coli, Female, Humans, *Mastitis, Microbial Sensitivity Tests, *Oils, Volatile/pharmacology, *Pharmaceutical Preparations | |
Pathogenicity | 35022718 | Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure. | Gaillard T, Dupieux-Chabert C, Butin M, Dumitrescu O, Naceur O, Bouveyron C, Martra A, Bes M, Tristan A, Vandenesch F, Lina G, Laurent F, Rasigade JP | J Antimicrob Chemother | 10.1093/jac/dkab488 | 2022 | Anti-Bacterial Agents/pharmacology/therapeutic use, Humans, *Methicillin-Resistant Staphylococcus aureus, Microbial Sensitivity Tests, *Staphylococcal Infections/drug therapy, Staphylococcus aureus, Vancomycin/pharmacology, Vancomycin Resistance | |
35758685 | Subinhibitory Concentrations of Antibiotics Exacerbate Staphylococcal Infection by Inducing Bacterial Virulence. | Gao P, Wei Y, Wan RE, Wong KW, Iu HTV, Tai SSC, Li Y, Yam HCB, Halebeedu Prakash P, Chen JHK, Ho PL, Yuen KY, Davies J, Kao RYT | Microbiol Spectr | 10.1128/spectrum.00640-22 | 2022 | Animals, Anti-Bacterial Agents/pharmacology, *Bacteremia/drug therapy, *Methicillin-Resistant Staphylococcus aureus, Mice, Microbial Sensitivity Tests, *Peritonitis/drug therapy, Reproducibility of Results, *Staphylococcal Infections/drug therapy/microbiology, Tetracycline/pharmacology, Virulence Factors, beta-Lactams/pharmacology |
Reference
@id | authors | title | doi/url | catalogue |
---|---|---|---|---|
20215 | Parte, A.C., Sardà Carbasse, J., Meier-Kolthoff, J.P., Reimer, L.C. and Göker, M. | List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ | 10.1099/ijsem.0.004332 | |
39515 | Curators of the CIP | https://catalogue-crbip.pasteur.fr/fiche_catalogue.xhtml?crbip=CIP%20106415 | Collection of Institut Pasteur (CIP 106415) | |
56732 | Curators of the CCUG | https://www.ccug.se/strain?id=45316 | Culture Collection University of Gothenburg (CCUG) (CCUG 45316) | |
66792 | Julia Koblitz, Joaquim Sardà, Lorenz Christian Reimer, Boyke Bunk, Jörg Overmann | Automatically annotated for the DiASPora project (Digital Approaches for the Synthesis of Poorly Accessible Biodiversity Information) | https://diaspora-project.de/progress.html#genomes | |
68375 | Automatically annotated from API ID32STA | |||
68382 | Automatically annotated from API zym | |||
69480 | Julia Koblitz, Joaquim Sardà, Lorenz Christian Reimer, Boyke Bunk, Jörg Overmann | Predictions based on genome sequence made in the Diaspora project (Digital Approaches for the Synthesis of Poorly Accessible Biodiversity Information) | https://diaspora-project.de/progress.html#genomes |